Search
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.
Silver
go.drugbank.com/drugs/DB12965ApprovedInvestigationalIt has a high electrical conductivity, thermal conductivity, and reflectivity. Silver exists as a pure elemental form, alloy with other metals, and mineral.
Demecarium
go.drugbank.com/drugs/DB00944ApprovedCholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it
Thioridazine
go.drugbank.com/drugs/DB00679ApprovedWithdrawnThioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618).
Alglucosidase alfa
go.drugbank.com/drugs/DB01272ApprovedInvestigationalIt is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen.
Cetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawn[L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]
Fitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770] … [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.
Idecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
Regadenoson
go.drugbank.com/drugs/DB06213ApprovedInvestigationalManufactured by Astellas and FDA approved April 10, 2008.